Inactive Instrument

Cellular Biomedicine Group, Inc. Stock price

Equities

CBMG

US15117P1021

Biotechnology & Medical Research

Dynamic Chart
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer CI
Cellular Biomedicine Group Announces FDA Clearance of Investigational New Drug Application for Novel TIL Therapy C-TIL051 CI
Cellular Biomedicine Group Inc Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma CI
Cellular Biomedicine Group Inc. Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma CI
Cellular Biomedicine Group, Inc. announced that it has received $120 million in funding from CICC Capital Management Co., Ltd., AstraZeneca PLC, Investment Arm, Yunfeng Capital, GIC Pte. Ltd., TF Capital, Sequoia China Investment Management LLP and other investors CI
Hillhouse Capital Provides Information to Shareholders of Hillhouse Capital CI
Cellular Biomedicine : Completes Merger with CBMG Holdings; Shares to No Longer Trade on Nasdaq MT
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from S&P Global BMI Index CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from S&P TMI Index CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from NASDAQ Composite Index CI
A consortium of buyers completed the acquisition of remaining 52.34% stake in Cellular Biomedicine Group, Inc. from a group of shareholders. CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Defensive Index CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Dynamic Index CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Growth-Defensive Index CI
Cellular Biomedicine Group, Inc.(NasdaqGS:CBMG) dropped from Russell 2000 Value-Defensive Index CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 13-02-05
Chief Tech/Sci/R&D Officer 57 15-07-31
Corporate Officer/Principal - -
Members of the board TitleAgeSince
Director/Board Member 77 19-10-11
Chief Executive Officer 60 13-02-05
Director/Board Member 51 14-11-10
More insiders
Cellular Biomedicine Group, Inc. (CBMG), is a clinical-stage biopharmaceutical company. The Company is leveraging its cell-based technologies to develop immunotherapies for the treatment of cancer and stem cell therapies for the treatment of degenerative diseases. The Company provides comprehensive and integrated research and manufacturing services throughout the discovery, development and manufacturing spectrum for cell-based technologies. The Company's primary focus has been to serve the growing health care market initially in China by marketing and commercializing immune cell and stem cell therapeutics, related tools and products. The Company's treatment focal points are cancer and Knee Osteoarthritis (KOA). It is focusing its clinical development efforts on assets such as C-CAR088, C-CAR039, TIL051, AFT-TCRT in China and/or United States. It has also completed a Phase-I/IIa clinical study, in China, for our KOA therapy named ReJoin.
More about the company
  1. Stock
  2. Equities
  3. Stock Cellular Biomedicine Group, Inc. - Nasdaq